Riskpilot← Back to searchSign inGet full accessPRE VENTION AS
ASActiveOrg 917734453Lørenveien 73A, 0585 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2024
NOK 0
EBITDA margin
—
+80% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
NOK -15K
+80% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -15K | +80% |
| Net profit | NOK -15K | +80% |
| Total assets | NOK 986K | -2% |
| Equity | NOK 986K | -2% |
| Employees | 0 | — |
Legal name
PRE VENTION AS
Org number
917734453
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29. september 2016
Share capital
NOK 40 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller to styremedlemmer i fellesskap. Daglig leder og ett styremedlem i fellesskap.
Company purpose
Utvikling, produksjon og distribusjon av intervensjonsprodukter innen forstadier til sykdommer, samt annen virksomhet som står i forbindelse med dette.
Address
Lørenveien 73A, 0585 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −136 | −192 | −362 | −76 | −15 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −136 | −192 | −362 | −76 | −15 |
| Net financials | 1 | 0 | −1 | −2 | 0 |
| Profit before tax | −135 | −191 | −362 | −78 | −15 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −135 | −191 | −362 | −78 | −15 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 651 | 1 623 | 1 092 | 1 001 | 986 |
| Equity | 1 633 | 1 441 | 1 079 | 1 001 | 986 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 19 | 182 | 13 | 0 | 0 |
| Total debt | 19 | 182 | 13 | 0 | 0 |
EBITDA margin
-1532500.0%
This company
15.8%
Market median
-9699467% vs market
20202024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
-1.6%
This company
18.4%
Market median
-109% vs market
20202024
Net profit margin
-1532500.0%
This company
8.1%
Market median
-18919853% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
CS Chief Executive Officer | Chief Executive Officer | 2019 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 81.25% | 81.25% | 2022 | |
| Company | 12.5% | 12.5% | 2022 | |
| Company | 3.12% | 3.12% | 2022 | |
| Company | 3.12% | 3.12% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pre Diagnostics As
PRE VENTION AS Board members of PRE VENTION AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Charlotte Sofie Bergsagel Berg-Svendsen | Chief Executive Officer | 0 companies |
| Håkon Sæterøy | Chairman | 0 companies |
| Atle Skattebøl | Board of Directors | 0 companies |
| Kathryn Moore Baker | Board of Directors | 0 companies |